Ruxolitinib (sulfate)

Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.

Product Specifications

CAS Number

[1092939-16-6]

Product Name Alternative

INCB018424 sulfate

UNSPSC

12352005

Target

Autophagy; JAK

Type

Reference compound

Related Pathways

Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ruxolitinib-sulfate.html

Purity

98.26

Solubility

10 mM in DMSO

Smiles

[H][C@@](C1CCCC1)(N2N=CC(C3=C4C=CNC4=NC=N3)=C2)CC#N.O=S(O)(O)=O

Molecular Formula

C17H20N6O4S

Molecular Weight

404.44

References & Citations

[1]Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115 (15), 3109-3117.|[2]Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012, 366 (9), 799-807.|[3]Harrison C, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 Mar 1;366 (9) :787-98.